PT1244438E - Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa - Google Patents
Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externaInfo
- Publication number
- PT1244438E PT1244438E PT00983818T PT00983818T PT1244438E PT 1244438 E PT1244438 E PT 1244438E PT 00983818 T PT00983818 T PT 00983818T PT 00983818 T PT00983818 T PT 00983818T PT 1244438 E PT1244438 E PT 1244438E
- Authority
- PT
- Portugal
- Prior art keywords
- antagonists
- perturbaces
- beta
- manufacture
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16799399P | 1999-11-30 | 1999-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1244438E true PT1244438E (pt) | 2004-02-27 |
Family
ID=22609644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT00983818T PT1244438E (pt) | 1999-11-30 | 2000-11-29 | Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa |
Country Status (18)
Country | Link |
---|---|
US (4) | US7081482B2 (pt) |
EP (1) | EP1244438B1 (pt) |
JP (2) | JP4758581B2 (pt) |
CN (1) | CN1245966C (pt) |
AT (1) | ATE253905T1 (pt) |
AU (1) | AU782524B2 (pt) |
BR (1) | BR0015938A (pt) |
CA (1) | CA2388728C (pt) |
DE (1) | DE60006584T2 (pt) |
DK (1) | DK1244438T3 (pt) |
ES (1) | ES2210023T3 (pt) |
HK (1) | HK1047695B (pt) |
MX (1) | MXPA02005378A (pt) |
PL (1) | PL214875B1 (pt) |
PT (1) | PT1244438E (pt) |
TR (1) | TR200302008T4 (pt) |
WO (1) | WO2001043737A1 (pt) |
ZA (1) | ZA200203133B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1245966C (zh) * | 1999-11-30 | 2006-03-22 | 爱尔康公司 | β-肾上腺素受体拮抗剂用于制备治疗外层视网膜疾病的药物的用途 |
CN100413503C (zh) * | 2005-01-07 | 2008-08-27 | 冷文 | 一种复方眼药组合物 |
US20080153819A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor |
US20110003816A1 (en) * | 2008-03-07 | 2011-01-06 | Sun Pharma Advanced Research Company Limited | Ophthalmic composition |
US10267796B2 (en) * | 2010-10-25 | 2019-04-23 | The Procter & Gamble Company | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
KR20190138683A (ko) * | 2017-04-21 | 2019-12-13 | 스티븐 호프만 | 망막병증을 치료하기 위한 조성물 및 방법 |
WO2019213358A1 (en) * | 2018-05-03 | 2019-11-07 | Alimera Sciences, Inc. | Methods of treating retinal diseases |
EP4180033A1 (en) * | 2020-07-10 | 2023-05-17 | Chang Gung Memorial Hospital, Linkou | USE OF ß-1 ADRENOCEPTOR ANTAGONIST FOR PREPARING COMPOSITION FOR REDUCING EPITHELIAL CELL DAMAGE INDUCED BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR AND INHIBITING CANCER CELLS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2330383A1 (fr) | 1975-11-06 | 1977-06-03 | Synthelabo | Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment |
US4443432A (en) | 1981-10-05 | 1984-04-17 | Alcon Laboratories, Inc. | Ophthmalic irrigating solution |
US5554367A (en) * | 1984-10-31 | 1996-09-10 | Alcon Laboratories, Inc. | Compositions for treatment of glaucoma |
WO1998010758A1 (en) | 1996-09-13 | 1998-03-19 | The Regents Of The University Of California | Methods for treatment of retinal diseases |
JP2003517441A (ja) * | 1998-09-25 | 2003-05-27 | アルコン ラボラトリーズ, インコーポレイテッド | 徐放性で快適な眼疾病用組成物および眼疾病の治療方法 |
CN1245966C (zh) | 1999-11-30 | 2006-03-22 | 爱尔康公司 | β-肾上腺素受体拮抗剂用于制备治疗外层视网膜疾病的药物的用途 |
-
2000
- 2000-11-29 CN CNB008163510A patent/CN1245966C/zh not_active Expired - Fee Related
- 2000-11-29 AT AT00983818T patent/ATE253905T1/de active
- 2000-11-29 DK DK00983818T patent/DK1244438T3/da active
- 2000-11-29 CA CA002388728A patent/CA2388728C/en not_active Expired - Fee Related
- 2000-11-29 WO PCT/US2000/032575 patent/WO2001043737A1/en active IP Right Grant
- 2000-11-29 US US10/130,408 patent/US7081482B2/en not_active Expired - Fee Related
- 2000-11-29 MX MXPA02005378A patent/MXPA02005378A/es active IP Right Grant
- 2000-11-29 AU AU20527/01A patent/AU782524B2/en not_active Ceased
- 2000-11-29 JP JP2001544676A patent/JP4758581B2/ja not_active Expired - Fee Related
- 2000-11-29 PL PL356001A patent/PL214875B1/pl unknown
- 2000-11-29 DE DE60006584T patent/DE60006584T2/de not_active Expired - Lifetime
- 2000-11-29 BR BR0015938-7A patent/BR0015938A/pt not_active Application Discontinuation
- 2000-11-29 TR TR2003/02008T patent/TR200302008T4/xx unknown
- 2000-11-29 PT PT00983818T patent/PT1244438E/pt unknown
- 2000-11-29 ES ES00983818T patent/ES2210023T3/es not_active Expired - Lifetime
- 2000-11-29 EP EP00983818A patent/EP1244438B1/en not_active Expired - Lifetime
-
2002
- 2002-04-19 ZA ZA200203133A patent/ZA200203133B/en unknown
- 2002-11-16 HK HK02108325.7A patent/HK1047695B/zh not_active IP Right Cessation
-
2006
- 2006-05-02 US US11/415,824 patent/US20060199868A1/en not_active Abandoned
-
2008
- 2008-01-04 US US11/969,346 patent/US20080103211A1/en not_active Abandoned
-
2010
- 2010-06-09 US US12/796,942 patent/US8710102B2/en not_active Expired - Fee Related
- 2010-07-06 JP JP2010154379A patent/JP2010215667A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2388728A1 (en) | 2001-06-21 |
HK1047695B (zh) | 2004-08-20 |
PL214875B1 (pl) | 2013-09-30 |
TR200302008T4 (tr) | 2004-01-21 |
DK1244438T3 (da) | 2004-02-23 |
CN1402634A (zh) | 2003-03-12 |
HK1047695A1 (en) | 2003-03-07 |
WO2001043737A1 (en) | 2001-06-21 |
AU782524B2 (en) | 2005-08-04 |
DE60006584D1 (de) | 2003-12-18 |
ZA200203133B (en) | 2003-04-22 |
EP1244438B1 (en) | 2003-11-12 |
CA2388728C (en) | 2009-05-19 |
BR0015938A (pt) | 2002-08-27 |
JP4758581B2 (ja) | 2011-08-31 |
DE60006584T2 (de) | 2004-09-30 |
MXPA02005378A (es) | 2005-02-25 |
US20100249134A1 (en) | 2010-09-30 |
CN1245966C (zh) | 2006-03-22 |
EP1244438A1 (en) | 2002-10-02 |
ATE253905T1 (de) | 2003-11-15 |
AU2052701A (en) | 2001-06-25 |
US8710102B2 (en) | 2014-04-29 |
US20060199868A1 (en) | 2006-09-07 |
PL356001A1 (en) | 2004-05-31 |
US20020193373A1 (en) | 2002-12-19 |
US20080103211A1 (en) | 2008-05-01 |
US7081482B2 (en) | 2006-07-25 |
JP2003516963A (ja) | 2003-05-20 |
JP2010215667A (ja) | 2010-09-30 |
ES2210023T3 (es) | 2004-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL144643A0 (en) | Jak-3 inhibitors for treating allergic disorders | |
PT1263504E (pt) | Compostos com actividade 5-ht1a uteis para o tratamento de perturbacoes da retina externa | |
PL352229A1 (en) | Prosthesis of sclera for treatment of presbyopia and other sight disorders | |
HK1074577A1 (en) | The use of thymosin ß4 (Tß4), analogues, isoforms and other derivatives in the manufacture of a medicament for treating disorders of eye and the surrounding tissue | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
SE9704644D0 (sv) | New use | |
BR0210013A (pt) | Gel oftálmico de pirenzepina | |
PT946157E (pt) | Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular | |
PT1244438E (pt) | Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa | |
AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa | |
TR200200014T2 (tr) | Nörotik düzensizliklerin tedavisi. | |
EE200100553A (et) | Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks | |
PT966285E (pt) | Utilizacao de (+)mefloquina para o tratamento da malaria | |
RS52011B (sr) | Nova primena derivata taksoida | |
WO2003015690A3 (en) | Method for treating primary insomnia | |
EE200100689A (et) | IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon | |
DK0871446T3 (da) | Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve | |
NO990450L (no) | Behandling av sinnslidelser | |
BG105984A (bg) | Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението | |
AR026062A1 (es) | Tratamiento de desordenes oculares | |
EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders | |
BG108033A (en) | Use of 2-amino-1-(4-hydroxy-2-methane sulphonamidophenyl)ethanol for treating urinary incontinence. | |
AUPQ330599A0 (en) | Novel agents for treatment and diagnosis of ocular disorders |